ISB News

Maternal COVID-19 Infection Increases Risks of Preterm Birth, Low Birth Weight and Stillbirth

People who contracted COVID-19 while pregnant were more likely to have poor birth outcomes including preterm birth, small for gestational age, low birth weight, and stillbirth. The poor outcomes of preterm birth and stillbirth were observed primarily with those infected with SARS-CoV-2 during the first or second trimester, whereas increased rates of small for gestational age were driven largely by third trimester infection.

An Institute for Systems Biology-led study examined the electronic health records of more than 18,000 people with SARS-CoV-2 tests during pregnancy. Researchers compared outcomes of unvaccinated people with a positive test during pregnancy – 882 in total – to those who tested negative.

“We found that SARS-CoV-2 infection indicated increased rates of preterm delivery and stillbirth, largely driven by first and second trimester infections,” said ISB Postdoctoral Fellow and K. Carole Ellison Fellow Dr. Samantha Piekos, first author of the study. She added: “The single greatest predictor of gestational age at delivery is gestational age at infection, with earlier age at infection associated with earlier age at delivery.”

The people in the study had mild or moderate SARS-CoV-2 infections. Severity of maternal COVID-19 infection was not correlated with gestational age at delivery. Additionally, poor birth outcomes were present even if maternal COVID-19 didn’t result in severe respiratory problems during infection.

Drs. Jennifer Hadlock and Samantha Piekos

ISB Assistant Professor Dr. Jennifer Hadlock, left, and Postdoctoral Fellow and K. Carole Ellison Fellow Dr. Samantha Piekos.

The findings were published today in the journal The Lancet Digital Health and are among the first that account for the trimester of SARS-CoV-2 infection on birth outcomes. 

People in the SARS-CoV-2-positive cohort were more likely to have Hispanic ethnicity, race other than Asian or White, Medicaid insurance, lower age, higher BMI, lower education attainment, and other factors known to be associated with negative birth outcomes. To account for this and to make a true apples-to-apples comparison, researchers used a statistical matching technique that controlled for the confounding variables.

“Pregnant people are at an increased risk of adverse outcomes following SARS-CoV-2 infection, even when maternal COVID-19 is less severe, and they may benefit from increased monitoring following infection,” said Dr. Jennifer Hadlock, corresponding author of the paper and assistant professor at ISB. “Both maternal and fetal health are at increased risk with COVID-19. Therefore, this reinforces the importance of protecting pregnant women,” she added.

The study was conducted before COVID-19 vaccines were widely available in the United States. There is an opportunity for future studies to examine whether vaccination helps to prevent negative birth outcomes in breakthrough cases.

Recent Articles

  • Dr. Sean Gibbons Promoted to Associate Professor

    Dr. Sean Gibbons – an expert in microbial ecology and evolution, computational systems biology, the human gut microbiome and its impacts on health, and head of ISB’s Gibbons Lab – has been promoted to Associate Professor. “Sean’s achievements since joining ISB in 2018 as a Washington Research Foundation Distinguished Investigator have been spectacular,” ISB President Dr. Jim Heath said. “With his focus on the microbiome, he brought a whole new…

  • AmeriCorps Member Sara Calder Joins ISB as Systems Health and STEM Coordinator

    Sara Calder recently joined ISB as Systems Health and STEM Coordinator, and is our second-ever AmeriCorps member. In this Q&A, Calder shares her education journey, her future plans, and much more.

  • In First-of-Its-Kind Trial, Scientists Use CRISPR to Treat Cancer

    Scientists for the first time have used CRISPR to substitute a gene to treat patients with cancer. The remarkable findings were published in the journal Nature and presented at the Society for Immunotherapy of Cancer (SITC) 2022.